Growth factors and receptors as prognostic markers in urothelial carcinoma.
Growth factors and receptors as prognostic markers in urothelial carcinoma.
复制标题
DOI：
10.1007/s11934-008-0011-6
复制
发表时间：
2008-01-01
影响因子：
2.6
通讯作者：
Dinney, Colin P N
中科院分区：
文献类型：
--
作者：
Black, Peter C;Dinney, Colin P N
生长因子及其受体在膀胱移行细胞癌的生物学过程中具有重要意义。在这种情况下，基因表达、扩增和突变的表征已经确立了受体作为新型治疗剂潜在靶点的相关性。由于这些特征因疾病状态而异，它们可以作为复发、进展、治疗反应和死亡率的预后指标。本文综述了人表皮生长因子受体家族的预后价值，包括表皮生长因子受体（EGFR）、人EGFR-2 （HER2）、HER3、HER4、血管内皮生长因子受体（VEGFR）和成纤维细胞生长因子受体-3 （FGFR3）。EGFR和HER2似乎预示预后不良，而HER4和FGFR3似乎是有利的预后指标。然而，需要验证研究来回答许多剩余的问题。
Growth factors and their receptors are significant to the biology of transitional cell carcinoma of the bladder. In this context, characterization of gene expression, amplification, and mutation has established the relevance of receptors as potential targets of novel therapeutic agents. Because these characteristics vary across disease states, they may serve as prognostic indicators of recurrence, progression, response to therapy, and mortality. This review focuses on the prognostic value of the human epidermal growth factor receptor family, including epidermal growth factor receptor (EGFR), human EGFR-2 (HER2), HER3, HER4, vascular endothelial growth factor receptor (VEGFR), and fibroblast growth factor receptor-3 (FGFR3). EGFR and HER2 seem to indicate a poor prognosis, and HER4 and FGFR3 appear to be favorable prognostic indicators. However, validation studies are required to answer many remaining questions.